Literature DB >> 27637864

Disease severity and erythropoiesis in chronic hepatitis C.

Chung-Feng Huang1,2, Ching-I Huang1, Ming-Lun Yeh1,2, Chen Hou3, Nai-Jen Hou4, Ming-Yen Hsieh4, Jee-Fu Huang1,2,5, Shinn-Cherng Chen1,2, Zu-Yau Lin1,2, Chia-Yen Dai1,2,5, Wan-Long Chuang1,2,5, Ming-Lung Yu1,2,5,6.   

Abstract

BACKGROUND/AIMS: The erythropoiesis in hepatitis C virus infection is unclear. We aimed to evaluate the erythropoietic components in chronic hepatitis C (CHC) patients.
METHODS: The red blood cell (RBC) components, serum erythropoietin (EPO) levels, and their relationship to clinical characteristics were evaluated between 124 age-matched and sex-matched healthy controls and 248 histology-proven CHC patients.
RESULTS: Chronic hepatitis C patients had significantly higher serum levels of EPO (1.44 ± 0.36 log mIU/mL versus 1.03 ± 0.31 log mIU/mL, P < 0.0001) and lower hemoglobin (Hb) concentrations (14.6 ± 1.4 g/dL versus 15.3 ± 1.2 g/dL, P < 0.001) as compared with healthy controls. Among the CHC patients, the serum EPO level was negatively associated with the Hb concentration (β = -0.227; 95% confidence intervals [CI]: -0.09-0.027; P < 0.001) and RBC counts (β = -0.204; 95% CI: -0.245-0.061; P = 0.001) and was positively correlated with necroinflammatory activity (β = 0.201; 95% CI: 0.009-0.046; P = 0.003) and fibrosis (β = 0.143; 95% CI: 0.003-0.076; P = 0.04) of liver histopathology. For non-cirrhotic CHC patients, the severity of liver necroinflammatory activity was positively correlated with the reticulocyte and serum EPO levels (P = 0.001 and 0.008, respectively), and negatively related to the RBC counts (P = 0.03). Using stepwise multivariate linear regression analysis, the grade of necroinflammatory activity was positive (β = 0.214; 95% CI: 0.046-0.209, P = 0.002), whereas the Hb concentration was inversely (β = -0.205; 95% CI: -0.09-0.018, P = 0.004) associated with the serum EPO levels in CHC patients.
CONCLUSIONS: The disease activity in CHC patients had a negative impact on erythropoiesis with compensatory higher but blunted EPO responses.
© 2016 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  CHC; EPO; HCV; fibrosis

Mesh:

Substances:

Year:  2017        PMID: 27637864     DOI: 10.1111/jgh.13600

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  2 in total

1.  The impact of antiretroviral therapy on iron homeostasis and inflammation markers in HIV-infected patients with mild anemia.

Authors:  Eugenia Quiros-Roldan; Francesco Castelli; Paola Lanza; Chiara Pezzoli; Marika Vezzoli; Giorgio Biasiotto; Isabella Zanella
Journal:  J Transl Med       Date:  2017-12-19       Impact factor: 5.531

2.  Changes in the Serum Hepcidin-to-ferritin Ratio with Erythroferrone after Hepatitis C Virus Eradication Using Direct-acting Antiviral Agents.

Authors:  Shinjiro Inomata; Akira Anan; Eri Yamauchi; Ryo Yamauchi; Hideo Kunimoto; Kazuhide Takata; Takashi Tanaka; Keiji Yokoyama; Daisuke Morihara; Yasuaki Takeyama; Makoto Irie; Satoshi Shakado; Tetsuro Sohda; Shotaro Sakisaka
Journal:  Intern Med       Date:  2019-06-27       Impact factor: 1.271

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.